Target $12.00 (was $11.17). In the view of UBS, UK pathology contracts offer both opportunity and risk for the company as outsourcing momentum is increasing.
To reflect the potential UBS has adjusted its price target for Sonic Health, the change enough to generate an upgrade to a Neutral rating.
Sector: Health Care Equipment & Services.
Target price is $12.00.Current Price is $11.61. Difference: $0.39 – (brackets indicate current price is over target). If SHL meets the UBS target it will return approximately 3% (excluding dividends, fees and charges – negative figures indicate an expected loss).